BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bienaime F, Dragon-Durey MA, Regnier CH, Nilsson SC, Kwan WH, Blouin J, Jablonski M, Renault N, Rameix-Welti MA, Loirat C. Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int. 2010;77:339-349. [PMID: 20016463 DOI: 10.1038/ki.2009.472] [Cited by in Crossref: 121] [Cited by in F6Publishing: 108] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Payette A, Patey N, Dragon-durey M, Frémeaux-bacchi V, Le Deist F, Lapeyraque A. A case of C3 glomerulonephritis successfully treated with eculizumab. Pediatr Nephrol 2015;30:1033-7. [DOI: 10.1007/s00467-015-3061-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
2 Johnson S, Waters A. Is complement a culprit in infection-induced forms of haemolytic uraemic syndrome? Immunobiology 2012;217:235-43. [PMID: 21852019 DOI: 10.1016/j.imbio.2011.07.022] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
3 Salmon JE, Heuser C, Triebwasser M, Liszewski MK, Kavanagh D, Roumenina L, Branch DW, Goodship T, Fremeaux-Bacchi V, Atkinson JP. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med. 2011;8:e1001013. [PMID: 21445332 DOI: 10.1371/journal.pmed.1001013] [Cited by in Crossref: 195] [Cited by in F6Publishing: 174] [Article Influence: 17.7] [Reference Citation Analysis]
4 Alasfar S, Alachkar N. Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature. Front Med (Lausanne) 2014;1:52. [PMID: 25593925 DOI: 10.3389/fmed.2014.00052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
5 Seddon JM, Yu Y, Miller EC, Reynolds R, Tan PL, Gowrisankar S, Goldstein JI, Triebwasser M, Anderson HE, Zerbib J, Kavanagh D, Souied E, Katsanis N, Daly MJ, Atkinson JP, Raychaudhuri S. Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. Nat Genet 2013;45:1366-70. [PMID: 24036952 DOI: 10.1038/ng.2741] [Cited by in Crossref: 198] [Cited by in F6Publishing: 187] [Article Influence: 22.0] [Reference Citation Analysis]
6 de Jong S, Volokhina EB, de Breuk A, Nilsson SC, de Jong EK, van der Kar NCAJ, Bakker B, Hoyng CB, van den Heuvel LP, Blom AM, den Hollander AI. Effect of rare coding variants in the CFI gene on Factor I expression levels. Hum Mol Genet 2020;29:2313-24. [PMID: 32510551 DOI: 10.1093/hmg/ddaa114] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
7 Nitzan-Luques A, Slae M, Zugayar D, Dixon BP, Meir K, Volovelsky O. Neonatal thrombotic microangiopathy secondary to factor I variant with Hirschsprung disease. J Nephrol 2021;34:241-5. [PMID: 32514992 DOI: 10.1007/s40620-020-00766-5] [Reference Citation Analysis]
8 Durán CE, Blasco M, Maduell F, Campistol JM. Rescue therapy with eculizumab in a transplant recipient with atypical haemolytic-uraemic syndrome. Clin Kidney J 2012;5:28-30. [PMID: 26069742 DOI: 10.1093/ndtplus/sfr107] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
9 Nilsson SC, Blom AM. Purification and Functional Characterization of Factor I. In: Gadjeva M, editor. The Complement System. Totowa: Humana Press; 2014. pp. 177-88. [DOI: 10.1007/978-1-62703-724-2_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Zuber J, Le Quintrec M, Sberro-soussan R, Loirat C, Frémeaux-bacchi V, Legendre C. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 2011;7:23-35. [DOI: 10.1038/nrneph.2010.155] [Cited by in Crossref: 124] [Cited by in F6Publishing: 92] [Article Influence: 10.3] [Reference Citation Analysis]
11 Timmermans SAMEG, Damoiseaux JGMC, Werion A, Reutelingsperger CP, Morelle J, van Paassen P. Functional and Genetic Landscape of Complement Dysregulation Along the Spectrum of Thrombotic Microangiopathy and its Potential Implications on Clinical Outcomes. Kidney Int Rep 2021;6:1099-109. [PMID: 33912760 DOI: 10.1016/j.ekir.2021.01.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Kavanagh D, Yu Y, Schramm EC, Triebwasser M, Wagner EK, Raychaudhuri S, Daly MJ, Atkinson JP, Seddon JM. Rare genetic variants in the CFI gene are associated with advanced age-related macular degeneration and commonly result in reduced serum factor I levels. Hum Mol Genet 2015;24:3861-70. [PMID: 25788521 DOI: 10.1093/hmg/ddv091] [Cited by in Crossref: 21] [Cited by in F6Publishing: 45] [Article Influence: 3.0] [Reference Citation Analysis]
13 van de Ven JPH, Nilsson SC, Tan PL, Buitendijk GHS, Ristau T, Mohlin FC, Nabuurs SB, Schoenmaker-koller FE, Smailhodzic D, Campochiaro PA, Zack DJ, Duvvari MR, Bakker B, Paun CC, Boon CJF, Uitterlinden AG, Liakopoulos S, Klevering BJ, Fauser S, Daha MR, Katsanis N, Klaver CCW, Blom AM, Hoyng CB, den Hollander AI. A functional variant in the CFI gene confers a high risk of age-related macular degeneration. Nat Genet 2013;45:813-7. [DOI: 10.1038/ng.2640] [Cited by in Crossref: 109] [Cited by in F6Publishing: 106] [Article Influence: 12.1] [Reference Citation Analysis]
14 Szilágyi A, Kiss N, Bereczki C, Tálosi G, Rácz K, Túri S, Györke Z, Simon E, Horváth E, Kelen K, Reusz GS, Szabó AJ, Tulassay T, Prohászka Z. The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome. Nephrol Dial Transplant 2013;28:2237-45. [PMID: 23787556 DOI: 10.1093/ndt/gft198] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
15 Haerynck F, Stordeur P, Vandewalle J, Van Coster R, Bordon V, De Baets F, Schelstraete P, Javaux C, Bouvry M, Fremeaux-bacchi V, Dehoorne J. Complete Factor I Deficiency Due to Dysfunctional Factor I with Recurrent Aseptic Meningo-Encephalitis. J Clin Immunol 2013;33:1293-301. [DOI: 10.1007/s10875-013-9944-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
16 El Sissy C, Rosain J, Vieira-Martins P, Bordereau P, Gruber A, Devriese M, de Pontual L, Taha MK, Fieschi C, Picard C, Frémeaux-Bacchi V. Clinical and Genetic Spectrum of a Large Cohort With Total and Sub-total Complement Deficiencies. Front Immunol 2019;10:1936. [PMID: 31440263 DOI: 10.3389/fimmu.2019.01936] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
17 Fayek SA, Allam SR, Martinez E, Pan G, Dao A, Rofaiel G. Atypical Hemolytic Uremic Syndrome After Kidney Transplantation: Lessons Learned From the Good, the Bad, and the Ugly. A Case Series With Literature Review. Transplant Proc 2020;52:146-52. [PMID: 31924403 DOI: 10.1016/j.transproceed.2019.10.015] [Reference Citation Analysis]
18 Fakhouri F, Fila M, Provôt F, Delmas Y, Barbet C, Châtelet V, Rafat C, Cailliez M, Hogan J, Servais A, Karras A, Makdassi R, Louillet F, Coindre JP, Rondeau E, Loirat C, Frémeaux-Bacchi V. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. Clin J Am Soc Nephrol 2017;12:50-9. [PMID: 27799617 DOI: 10.2215/CJN.06440616] [Cited by in Crossref: 94] [Cited by in F6Publishing: 43] [Article Influence: 15.7] [Reference Citation Analysis]
19 Lee JM, Park YS, Lee JH, Park SJ, Shin JI, Park YH, Yoo KH, Cho MH, Kim SY, Kim SH, Namgoong MK, Lee SJ, Lee JH, Cho HY, Han KH, Kang HG, Ha IS, Bae JS, Kim NK, Park WY, Cheong HI. Atypical hemolytic uremic syndrome: Korean pediatric series. Pediatr Int 2015;57:431-8. [PMID: 25443527 DOI: 10.1111/ped.12549] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
20 de Breuk A, Acar IE, Kersten E, Schijvenaars MMVAP, Colijn JM, Haer-Wigman L, Bakker B, de Jong S, Meester-Smoor MA, Verzijden T, Missotten TOAR, Monés J, Biarnés M, Pauleikhoff D, Hense HW, Silva R, Nunes S, Melo JB, Fauser S, Hoyng CB, Ueffing M, Coenen MJH, Klaver CCW, den Hollander AI; EYE-RISK Consortium. Development of a Genotype Assay for Age-Related Macular Degeneration: The EYE-RISK Consortium. Ophthalmology 2020:S0161-6420(20)30725-9. [PMID: 32717343 DOI: 10.1016/j.ophtha.2020.07.037] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
21 Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8:643-657. [PMID: 23026949 DOI: 10.1038/nrneph.2012.214] [Cited by in Crossref: 349] [Cited by in F6Publishing: 291] [Article Influence: 34.9] [Reference Citation Analysis]
22 Gaut JP, Jain S, Pfeifer JD, Vigh-Conrad KA, Corliss M, Sharma MK, Heusel JW, Cottrell CE. Routine use of clinical exome-based next-generation sequencing for evaluation of patients with thrombotic microangiopathies. Mod Pathol 2017;30:1739-47. [PMID: 28752844 DOI: 10.1038/modpathol.2017.90] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
23 Jourde-Chiche N, Fakhouri F, Dou L, Bellien J, Burtey S, Frimat M, Jarrot PA, Kaplanski G, Le Quintrec M, Pernin V, Rigothier C, Sallée M, Fremeaux-Bacchi V, Guerrot D, Roumenina LT. Endothelium structure and function in kidney health and disease. Nat Rev Nephrol 2019;15:87-108. [PMID: 30607032 DOI: 10.1038/s41581-018-0098-z] [Cited by in Crossref: 104] [Cited by in F6Publishing: 98] [Article Influence: 34.7] [Reference Citation Analysis]
24 Han SS, Yu XJ, Wang SX, Zhou FD, Yu F, Zhao MH. A novel mutation in complement 2 accompanied by susceptibility variants in C3 glomerulonephritis: A case study. Nefrologia (Engl Ed) 2019;39:664-71. [PMID: 31014550 DOI: 10.1016/j.nefro.2019.01.008] [Reference Citation Analysis]
25 Riedl M, Hofer J, Giner T, Rosales A, Häffner K, Simonetti GD, Walden U, Maier T, Heininger D, Jeller V, Weiss G, van den Heuvel L, Zimmerhackl LB, Würzner R, Jungraithmayr TC. Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab. J Immunol Methods 2016;435:60-7. [PMID: 27238216 DOI: 10.1016/j.jim.2016.05.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
26 Salvadori M, Bertoni E. Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations. World J Nephrol 2013; 2(3): 56-76 [PMID: 24255888 DOI: 10.5527/wjn.v2.i3.56] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 44] [Article Influence: 7.1] [Reference Citation Analysis]
27 Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012;8:622-33. [PMID: 22986360 DOI: 10.1038/nrneph.2012.195] [Cited by in Crossref: 247] [Cited by in F6Publishing: 218] [Article Influence: 24.7] [Reference Citation Analysis]
28 Zhao W, Ding Y, Lu J, Zhang T, Chen D, Zhang H, Zeng C, Liu Z, Chen H. Genetic analysis of the complement pathway in C3 glomerulopathy. Nephrol Dial Transplant 2018;33:1919-27. [PMID: 29566171 DOI: 10.1093/ndt/gfy033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
29 Duvvari MR, Paun CC, Buitendijk GH, Saksens NT, Volokhina EB, Ristau T, Schoenmaker-Koller FE, van de Ven JP, Groenewoud JM, van den Heuvel LP, Hofman A, Fauser S, Uitterlinden AG, Klaver CC, Hoyng CB, de Jong EK, den Hollander AI. Analysis of rare variants in the C3 gene in patients with age-related macular degeneration. PLoS One 2014;9:e94165. [PMID: 24736606 DOI: 10.1371/journal.pone.0094165] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
30 Sánchez-Corral P, Melgosa M. Advances in understanding the aetiology of atypical Haemolytic Uraemic Syndrome. Br J Haematol 2010;150:529-42. [PMID: 20629662 DOI: 10.1111/j.1365-2141.2010.08295.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
31 Ávila A, Gavela E, Sancho A. Thrombotic Microangiopathy After Kidney Transplantation: An Underdiagnosed and Potentially Reversible Entity. Front Med (Lausanne) 2021;8:642864. [PMID: 33898482 DOI: 10.3389/fmed.2021.642864] [Reference Citation Analysis]
32 Marinozzi MC, Vergoz L, Rybkine T, Ngo S, Bettoni S, Pashov A, Cayla M, Tabarin F, Jablonski M, Hue C. Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign? J Am Soc Nephrol. 2014;25:2053-2065. [PMID: 24652797 DOI: 10.1681/asn.2013070796] [Cited by in Crossref: 68] [Cited by in F6Publishing: 39] [Article Influence: 8.5] [Reference Citation Analysis]
33 Vieira-martins P, El Sissy C, Bordereau P, Gruber A, Rosain J, Fremeaux-bacchi V. Defining the genetics of thrombotic microangiopathies. Transfusion and Apheresis Science 2016;54:212-9. [DOI: 10.1016/j.transci.2016.04.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
34 Nilsson SC, Sim RB, Lea SM, Fremeaux-bacchi V, Blom AM. Complement factor I in health and disease. Molecular Immunology 2011;48:1611-20. [DOI: 10.1016/j.molimm.2011.04.004] [Cited by in Crossref: 91] [Cited by in F6Publishing: 74] [Article Influence: 8.3] [Reference Citation Analysis]
35 Timmermans SAMEG, Abdul-Hamid MA, Potjewijd J, Theunissen ROMFIH, Damoiseaux JGMC, Reutelingsperger CP, van Paassen P; Limburg Renal Registry. C5b9 Formation on Endothelial Cells Reflects Complement Defects among Patients with Renal Thrombotic Microangiopathy and Severe Hypertension. J Am Soc Nephrol 2018;29:2234-43. [PMID: 29858281 DOI: 10.1681/ASN.2018020184] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 8.8] [Reference Citation Analysis]
36 Turley AJ, Gathmann B, Bangs C, Bradbury M, Seneviratne S, Gonzalez-Granado LI, Hackett S, Kutukculer N, Alachkar H, Hambleton S, Ritterbusch H, Kralickova P, Marodi L, Seidel MG, Dueckers G, Roesler J, Huissoon A, Baxendale H, Litzman J, Arkwright PD. Spectrum and management of complement immunodeficiencies (excluding hereditary angioedema) across Europe. J Clin Immunol 2015;35:199-205. [PMID: 25663093 DOI: 10.1007/s10875-015-0137-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
37 Buhlmann D, Eberhardt HU, Medyukhina A, Prodinger WM, Figge MT, Zipfel PF, Skerka C. FHR3 Blocks C3d-Mediated Coactivation of Human B Cells. J Immunol 2016;197:620-9. [PMID: 27279373 DOI: 10.4049/jimmunol.1600053] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
38 Hallam TM, Marchbank KJ, Harris CL, Osmond C, Shuttleworth VG, Griffiths H, Cree AJ, Kavanagh D, Lotery AJ. Rare Genetic Variants in Complement Factor I Lead to Low FI Plasma Levels Resulting in Increased Risk of Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci 2020;61:18. [PMID: 32516404 DOI: 10.1167/iovs.61.6.18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
39 Riedl M, Rosales A, Zimmerhackl LB, Jungraithmayr T. Actual and future strategies for transplantation in atypical HUS associated with mutations in factor H: Editorial. Pediatric Transplantation 2011;15:225-8. [DOI: 10.1111/j.1399-3046.2010.01345.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
40 Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, Bagga A. Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment. Ther Apher Dial 2019;23:4-21. [PMID: 30294946 DOI: 10.1111/1744-9987.12763] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
41 Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement System Part II: Role in Immunity. Front Immunol 2015;6:257. [PMID: 26074922 DOI: 10.3389/fimmu.2015.00257] [Cited by in Crossref: 353] [Cited by in F6Publishing: 385] [Article Influence: 50.4] [Reference Citation Analysis]
42 Wong MD, Patel C, McTaggart S, Wainwright CE. Atypical haemolytic uraemic syndrome in a child with cystic fibrosis. J Paediatr Child Health 2021. [PMID: 34008207 DOI: 10.1111/jpc.15571] [Reference Citation Analysis]
43 Kavanagh D, Goodship T. Genetics and complement in atypical HUS. Pediatr Nephrol 2010;25:2431-42. [PMID: 20526633 DOI: 10.1007/s00467-010-1555-5] [Cited by in Crossref: 117] [Cited by in F6Publishing: 98] [Article Influence: 9.8] [Reference Citation Analysis]
44 Adamski J. Thrombotic microangiopathy and indications for therapeutic plasma exchange. Hematology 2014;2014:444-9. [DOI: 10.1182/asheducation-2014.1.444] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
45 Tsai HM. Excessive activation of the complement system in atypical hemolytic uremic syndrome: is it ready for prime time? Kidney Int 2010;77:267-9. [PMID: 20118898 DOI: 10.1038/ki.2009.467] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
46 Kavanagh D, Pappworth IY, Anderson H, Hayes CM, Moore I, Hunze EM, Bennaceur K, Roversi P, Lea S, Strain L. Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon? Clin J Am Soc Nephrol. 2012;7:417-426. [PMID: 22223611 DOI: 10.2215/cjn.05750611] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
47 Boyer O, Niaudet P. Hemolytic uremic syndrome: new developments in pathogenesis and treatment. Int J Nephrol 2011;2011:908407. [PMID: 21876803 DOI: 10.4061/2011/908407] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
48 Zipfel PF, Heinen S, Skerka C. Thrombotic microangiopathies: new insights and new challenges. Curr Opin Nephrol Hypertens 2010;19:372-8. [PMID: 20539230 DOI: 10.1097/MNH.0b013e32833aff4a] [Cited by in Crossref: 40] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
49 Mele C, Remuzzi G, Noris M. Hemolytic uremic syndrome. Semin Immunopathol 2014;36:399-420. [PMID: 24526222 DOI: 10.1007/s00281-014-0416-x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 67] [Article Influence: 11.5] [Reference Citation Analysis]
50 Loirat C, Saland J, Bitzan M. Management of hemolytic uremic syndrome. Presse Med. 2012;41:e115-e135. [PMID: 22284541 DOI: 10.1016/j.lpm.2011.11.013] [Cited by in Crossref: 69] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
51 El Sissy C, Saldman A, Zanetta G, Martins PV, Poulain C, Cauchois R, Kaplanski G, Venetz JP, Bobot M, Dobosziewicz H, Daniel L, Koubi M, Sadallah S, Rotman S, Mousson C, Pascual M, Frémeaux-Bacchi V, Fakhouri F. COVID-19 as a potential trigger of complement-mediated atypical HUS. Blood 2021;138:1777-82. [PMID: 34482396 DOI: 10.1182/blood.2021012752] [Reference Citation Analysis]
52 Geerlings MJ, de Jong EK, den Hollander AI. The complement system in age-related macular degeneration: A review of rare genetic variants and implications for personalized treatment. Mol Immunol 2017;84:65-76. [PMID: 27939104 DOI: 10.1016/j.molimm.2016.11.016] [Cited by in Crossref: 76] [Cited by in F6Publishing: 77] [Article Influence: 12.7] [Reference Citation Analysis]
53 Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844-1859. [PMID: 20595690 DOI: 10.2215/cjn.02210310] [Cited by in Crossref: 584] [Cited by in F6Publishing: 274] [Article Influence: 48.7] [Reference Citation Analysis]
54 Vaughn JL, Moore JM, Cataland SR. Acute Systolic Heart Failure Associated with Complement-Mediated Hemolytic Uremic Syndrome. Case Rep Hematol 2015;2015:327980. [PMID: 26557394 DOI: 10.1155/2015/327980] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Davin JC, van de Kar NC. Advances and challenges in the management of complement-mediated thrombotic microangiopathies. Ther Adv Hematol 2015;6:171-85. [PMID: 26288712 DOI: 10.1177/2040620715577613] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
56 Baines AC, Brodsky RA. Complementopathies. Blood Rev 2017;31:213-23. [PMID: 28215731 DOI: 10.1016/j.blre.2017.02.003] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 10.8] [Reference Citation Analysis]
57 Avasare RS, Canetta PA, Bomback AS, Marasa M, Caliskan Y, Ozluk Y, Li Y, Gharavi AG, Appel GB. Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy: A Case Series. Clin J Am Soc Nephrol 2018;13:406-13. [PMID: 29326307 DOI: 10.2215/CJN.09080817] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
58 Rodriguez E, Rallapalli PM, Osborne AJ, Perkins SJ. New functional and structural insights from updated mutational databases for complement factor H, Factor I, membrane cofactor protein and C3. Biosci Rep 2014;34:e00146. [PMID: 25188723 DOI: 10.1042/BSR20140117] [Cited by in Crossref: 47] [Cited by in F6Publishing: 26] [Article Influence: 5.9] [Reference Citation Analysis]
59 Kościelska-Kasprzak K, Bartoszek D, Myszka M, Zabińska M, Klinger M. The complement cascade and renal disease. Arch Immunol Ther Exp (Warsz) 2014;62:47-57. [PMID: 24030732 DOI: 10.1007/s00005-013-0254-x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
60 Noris M, Remuzzi G. Genetics of Immune-Mediated Glomerular Diseases: Focus on Complement. Seminars in Nephrology 2017;37:447-63. [DOI: 10.1016/j.semnephrol.2017.05.018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
61 Naesens L, Smet J, Tavernier SJ, Schelstraete P, Hoste L, Lambrecht S, Verhelst H, van der Werff Ten Bosch J, Ferster A, Blumental S, Hilbert P, Kerre T, Vande Walle J, Licht C, Roumenina LT, Stordeur P, Haerynck F. Plasma C3d levels as a diagnostic marker for complete complement factor I deficiency. J Allergy Clin Immunol 2021;147:749-753.e2. [PMID: 32853637 DOI: 10.1016/j.jaci.2020.08.014] [Reference Citation Analysis]
62 Gleeson PJ, Wilson V, Cox TE, Sharma SD, Smith-Jackson K, Strain L, Lappin D, McHale T, Kavanagh D, Goodship TH. Chromosomal rearrangement-A rare cause of complement factor I associated atypical haemolytic uraemic syndrome. Immunobiology 2016;221:1124-30. [PMID: 27268256 DOI: 10.1016/j.imbio.2016.05.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
63 Lemaire M, Noone D, Lapeyraque AL, Licht C, Frémeaux-Bacchi V. Inherited Kidney Complement Diseases. Clin J Am Soc Nephrol 2021;16:942-56. [PMID: 33536243 DOI: 10.2215/CJN.11830720] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Kavanagh D, Goodship TH. Atypical hemolytic uremic syndrome: . Current Opinion in Hematology 2010;17:432-8. [DOI: 10.1097/moh.0b013e32833cae86] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
65 Xiang J, Li X, Chen Y, Lu Y, Yu M, Chen X, Zhang W, Zeng Y, Sun L, Chen S, Sha Z. Complement factor I from flatfish half-smooth tongue ( Cynoglossus semilaevis ) exhibited anti-microbial activities. Developmental & Comparative Immunology 2015;53:199-209. [DOI: 10.1016/j.dci.2015.06.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
66 Wong EK, Goodship TH, Kavanagh D. Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol 2013;56:199-212. [PMID: 23810412 DOI: 10.1016/j.molimm.2013.05.224] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 6.7] [Reference Citation Analysis]
67 Wei X, Li J, Zhan X, Tu L, Huang H, Wang Y. A novel missense mutation in complement factor I predisposes patients to atypical hemolytic uremic syndrome: a case report. J Med Case Rep 2022;16:101. [PMID: 35241161 DOI: 10.1186/s13256-022-03312-y] [Reference Citation Analysis]
68 Waters AM, Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol. 2011;26:41-57. [PMID: 20556434 DOI: 10.1007/s00467-010-1556-4] [Cited by in Crossref: 87] [Cited by in F6Publishing: 74] [Article Influence: 7.3] [Reference Citation Analysis]
69 Jlajla H, Dehman F, Jallouli M, Khedher R, Ayadi I, Zerzeri Y, Laadhar L, Sfar I, Mahfoudh A, Gorgi Y, Cheour E, Zouaghi K, Gargah T, Kallel Sellami M. Molecular basis of complement factor I deficiency in Tunisian atypical haemolytic and uraemic syndrome patients. Nephrology (Carlton) 2019;24:357-64. [PMID: 29292855 DOI: 10.1111/nep.13217] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
70 Zuber J, Le Quintrec M, Morris H, Frémeaux-Bacchi V, Loirat C, Legendre C. Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. Transplant Rev (Orlando). 2013;27:117-125. [PMID: 23937869 DOI: 10.1016/j.trre.2013.07.003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 6.2] [Reference Citation Analysis]
71 Salvadori M, Rosso G, Bertoni E. Complement involvement in kidney diseases: From physiopathology to therapeutical targeting. World J Nephrol 2015; 4(2): 169-184 [PMID: 25949931 DOI: 10.5527/wjn.v4.i2.169] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
72 Malina M, Roumenina LT, Seeman T, Le Quintrec M, Dragon-Durey MA, Schaefer F, Fremeaux-Bacchi V. Genetics of hemolytic uremic syndromes. Presse Med 2012;41:e105-14. [PMID: 22265161 DOI: 10.1016/j.lpm.2011.10.028] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
73 Khan AH, Sutton J, Cree AJ, Khandhadia S, De Salvo G, Tobin J, Prakash P, Arora R, Amoaku W, Charbel Issa P, MacLaren RE, Bishop PN, Peto T, Mohamed Q, Steel DH, Sivaprasad S, Bailey C, Menon G, Kavanagh D, Lotery AJ. Prevalence and phenotype associations of complement factor I mutations in geographic atrophy. Hum Mutat 2021;42:1139-52. [PMID: 34153144 DOI: 10.1002/humu.24242] [Reference Citation Analysis]
74 Knoop M, Haller H, Menne J. [Human genetics in atypical hemolytic uremic syndrome-its role in diagnosis and treatment]. Internist (Berl) 2018;59:799-804. [PMID: 29995248 DOI: 10.1007/s00108-018-0455-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
75 Skerka C, Chen Q, Fremeaux-Bacchi V, Roumenina LT. Complement factor H related proteins (CFHRs). Mol Immunol. 2013;56:170-180. [PMID: 23830046 DOI: 10.1016/j.molimm.2013.06.001] [Cited by in Crossref: 145] [Cited by in F6Publishing: 130] [Article Influence: 16.1] [Reference Citation Analysis]
76 Leroy V, Fremeaux-bacchi V, Peuchmaur M, Baudouin V, Deschênes G, Macher M, Loirat C. Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation. Pediatr Nephrol 2011;26:419-24. [DOI: 10.1007/s00467-010-1734-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
77 Vester U, Mache CJ. Pharmacological treatment of atypical hemolytic-uremic syndrome. Expert Opinion on Orphan Drugs 2014;2:123-35. [DOI: 10.1517/21678707.2014.872029] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
78 Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol. 2013;24:475-486. [PMID: 23431077 DOI: 10.1681/asn.2012090884] [Cited by in Crossref: 231] [Cited by in F6Publishing: 110] [Article Influence: 25.7] [Reference Citation Analysis]
79 Cataland SR, Wu HM. How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. Blood 2014;123:2478-84. [PMID: 24599547 DOI: 10.1182/blood-2013-11-516237] [Cited by in Crossref: 86] [Cited by in F6Publishing: 61] [Article Influence: 10.8] [Reference Citation Analysis]
80 Muff-Luett M, Nester CM. The Genetics of Ultra-Rare Renal Disease. J Pediatr Genet 2016;5:33-42. [PMID: 27617140 DOI: 10.1055/s-0036-1572515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
81 Broderick L, Gandhi C, Mueller JL, Putnam CD, Shayan K, Giclas PC, Peterson KS, Aceves SS, Sheets RM, Peterson BM, Newbury RO, Hoffman HM, Bastian JF. Mutations of complement factor I and potential mechanisms of neuroinflammation in acute hemorrhagic leukoencephalitis. J Clin Immunol 2013;33:162-71. [PMID: 22926405 DOI: 10.1007/s10875-012-9767-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
82 Karpman D, Loos S, Tati R, Arvidsson I. Haemolytic uraemic syndrome. J Intern Med 2017;281:123-48. [DOI: 10.1111/joim.12546] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
83 Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 2015;35:421-47. [PMID: 26456110 DOI: 10.1016/j.nefro.2015.07.005] [Cited by in Crossref: 88] [Cited by in F6Publishing: 63] [Article Influence: 12.6] [Reference Citation Analysis]
84 Salvadori M, Bertoni E. Complement related kidney diseases: Recurrence after transplantation. World J Transplant 2016; 6(4): 632-645 [PMID: 28058212 DOI: 10.5500/wjt.v6.i4.632] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
85 Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, Chatelet V, Mousson C, Mourad G, Bridoux F. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant. 2013;13:663-675. [PMID: 23356914 DOI: 10.1111/ajt.12077] [Cited by in Crossref: 153] [Cited by in F6Publishing: 139] [Article Influence: 17.0] [Reference Citation Analysis]
86 Abbas F, El Kossi M, Kim JJ, Sharma A, Halawa A. Thrombotic microangiopathy after renal transplantation: Current insights in de novo and recurrent disease. World J Transplantation 2018; 8(5): 122-141 [PMID: 30211021 DOI: 10.5500/wjt.v8.i5.122] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 8] [Article Influence: 4.8] [Reference Citation Analysis]
87 Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S. An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document. Nefrología (English Edition) 2015;35:421-47. [DOI: 10.1016/j.nefroe.2015.11.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
88 Bruel A, Kavanagh D, Noris M, Delmas Y, Wong EKS, Bresin E, Provôt F, Brocklebank V, Mele C, Remuzzi G, Loirat C, Frémeaux-Bacchi V, Fakhouri F. Hemolytic Uremic Syndrome in Pregnancy and Postpartum. Clin J Am Soc Nephrol 2017;12:1237-47. [PMID: 28596415 DOI: 10.2215/CJN.00280117] [Cited by in Crossref: 86] [Cited by in F6Publishing: 37] [Article Influence: 17.2] [Reference Citation Analysis]
89 Boon CJ, van de Ven JP, Hoyng CB, den Hollander AI, Klevering BJ. Cuticular drusen: Stars in the sky. Progress in Retinal and Eye Research 2013;37:90-113. [DOI: 10.1016/j.preteyeres.2013.08.003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
90 Zheng L, Zhang D, Cao W, Song WC, Zheng XL. Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy. Blood 2019;134:1095-105. [PMID: 31409673 DOI: 10.1182/blood.2019001040] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
91 Frémeaux-Bacchi V. [Pathophysiology of atypical hemolytic uremic syndrome. Ten years of progress, from laboratory to patient]. Biol Aujourdhui 2013;207:231-40. [PMID: 24594571 DOI: 10.1051/jbio/2013027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
92 Java A, Pozzi N, Love-Gregory LD, Heusel JW, Sung YJ, Hu Z, Bertram P, Liszewski MK, Cline LM, Ren Z, Atkinson JP. A Multimodality Approach to Assessing Factor I Genetic Variants in Atypical Hemolytic Uremic Syndrome. Kidney Int Rep 2019;4:1007-17. [PMID: 31312772 DOI: 10.1016/j.ekir.2019.04.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
93 Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011;6:60. [PMID: 21902819 DOI: 10.1186/1750-1172-6-60] [Cited by in Crossref: 375] [Cited by in F6Publishing: 304] [Article Influence: 34.1] [Reference Citation Analysis]
94 Tsai H. A Mechanistic Approach to the Diagnosis and Management of Atypical Hemolytic Uremic Syndrome. Transfusion Medicine Reviews 2014;28:187-97. [DOI: 10.1016/j.tmrv.2014.08.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
95 Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33:508-530. [PMID: 24161037 DOI: 10.1016/j.semnephrol.2013.08.003] [Cited by in Crossref: 204] [Cited by in F6Publishing: 156] [Article Influence: 25.5] [Reference Citation Analysis]
96 Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V. Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods. 2011;365:8-26. [PMID: 21215749 DOI: 10.1016/j.jim.2010.12.020] [Cited by in Crossref: 108] [Cited by in F6Publishing: 100] [Article Influence: 9.8] [Reference Citation Analysis]
97 Schejbel L, Schmidt IM, Kirchhoff M, Andersen CB, Marquart HV, Zipfel P, Garred P. Complement factor H deficiency and endocapillary glomerulonephritis due to paternal isodisomy and a novel factor H mutation. Genes Immun. 2011;12:90-99. [PMID: 21270828 DOI: 10.1038/gene.2010.63] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
98 Timmermans SAMEG, Abdul-Hamid MA, Vanderlocht J, Damoiseaux JGMC, Reutelingsperger CP, van Paassen P; Limburg Renal Registry. Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities. Kidney Int 2017;91:1420-5. [PMID: 28187980 DOI: 10.1016/j.kint.2016.12.009] [Cited by in Crossref: 63] [Cited by in F6Publishing: 50] [Article Influence: 12.6] [Reference Citation Analysis]
99 Roumenina LT, Roquigny R, Blanc C, Poulain N, Ngo S, Dragon-durey M, Frémeaux-bacchi V. Functional Evaluation of Factor H genetic and Acquired Abnormalities: Application for Atypical Hemolytic Uremic Syndrome (aHUS). In: Gadjeva M, editor. The Complement System. Totowa: Humana Press; 2014. pp. 237-47. [DOI: 10.1007/978-1-62703-724-2_19] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
100 Shatzel JJ, Taylor JA. Syndromes of Thrombotic Microangiopathy. Med Clin North Am 2017;101:395-415. [PMID: 28189178 DOI: 10.1016/j.mcna.2016.09.010] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
101 Ferreira E, Oliveira N, Marques M, Francisco L, Santos A, Carreira A, Campos M. Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3. Nefrologia 2016;36:72-5. [PMID: 26541438 DOI: 10.1016/j.nefro.2015.07.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
102 Goicoechea de Jorge E, López Lera A, Bayarri-Olmos R, Yebenes H, Lopez-Trascasa M, Rodríguez de Córdoba S. Common and rare genetic variants of complement components in human disease. Mol Immunol 2018;102:42-57. [PMID: 29914697 DOI: 10.1016/j.molimm.2018.06.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
103 Wong EKS, Kavanagh D. Diseases of complement dysregulation-an overview. Semin Immunopathol 2018;40:49-64. [PMID: 29327071 DOI: 10.1007/s00281-017-0663-8] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
104 Roumenina LT, Rayes J, Frimat M, Fremeaux-Bacchi V. Endothelial cells: source, barrier, and target of defensive mediators. Immunol Rev 2016;274:307-29. [PMID: 27782324 DOI: 10.1111/imr.12479] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 10.8] [Reference Citation Analysis]
105 Huerta A, Arjona E, Portoles J, Lopez-Sanchez P, Rabasco C, Espinosa M, Cavero T, Blasco M, Cao M, Manrique J, Cabello-Chavez V, Suñer M, Heras M, Fulladosa X, Belmar L, Sempere A, Peralta C, Castillo L, Arnau A, Praga M, Rodriguez de Cordoba S. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney Int 2018;93:450-9. [PMID: 28911789 DOI: 10.1016/j.kint.2017.06.022] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 10.4] [Reference Citation Analysis]
106 Gaggl M, Aigner C, Csuka D, Szilágyi Á, Prohászka Z, Kain R, Haninger N, Knechtelsdorfer M, Sunder-Plassmann R, Sunder-Plassmann G, Schmidt A. Maternal and Fetal Outcomes of Pregnancies in Women with Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol 2018;29:1020-9. [PMID: 29282226 DOI: 10.1681/ASN.2016090995] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 5.6] [Reference Citation Analysis]
107 Cheong HI, Jo SK, Yoon SS, Cho H, Kim JS, Kim YO, Koo JR, Park Y, Park YS, Shin JI, Yoo KH, Oh D. Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea. J Korean Med Sci 2016;31:1516-28. [PMID: 27550478 DOI: 10.3346/jkms.2016.31.10.1516] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
108 Schalk G, Kirschfink M, Wehling C, Gastoldi S, Bergmann C, Hoppe B, Weber LT. A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab. Pediatr Nephrol 2015;30:1039-42. [PMID: 25752761 DOI: 10.1007/s00467-015-3078-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
109 Nester CM, Barbour T, de Cordoba SR, Dragon-Durey MA, Fremeaux-Bacchi V, Goodship TH, Kavanagh D, Noris M, Pickering M, Sanchez-Corral P. Atypical aHUS: State of the art. Mol Immunol. 2015;67:31-42. [PMID: 25843230 DOI: 10.1016/j.molimm.2015.03.246] [Cited by in Crossref: 162] [Cited by in F6Publishing: 136] [Article Influence: 23.1] [Reference Citation Analysis]
110 Servais A, Noël LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, Macher MA, Zuber J, Karras A, Provot F. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012;82:454-464. [PMID: 22456601 DOI: 10.1038/ki.2012.63] [Cited by in Crossref: 328] [Cited by in F6Publishing: 285] [Article Influence: 32.8] [Reference Citation Analysis]
111 Barbour T, Johnson S, Cohney S, Hughes P. Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant. 2012;27:2673-2685. [PMID: 22802583 DOI: 10.1093/ndt/gfs279] [Cited by in Crossref: 121] [Cited by in F6Publishing: 93] [Article Influence: 12.1] [Reference Citation Analysis]
112 Zwang NA, Ho B, Kanwar YS, Lewis B, Cusick M, Friedewald JJ, Gallon L. A case of atypical hemolytic uremic syndrome in a second renal transplant. J Nephrol 2018;31:165-72. [PMID: 28224376 DOI: 10.1007/s40620-016-0373-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]